# Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia

> **NCT05998759** · PHASE2 · RECRUITING · sponsor: **Beijing Hospital** · enrollment: 296 (estimated)

## Conditions studied

- Connective Tissue Diseases
- Thrombocytopenia

## Interventions

- **BIOLOGICAL:** Telitacicept
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05998759
- **Lead sponsor:** Beijing Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-02
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 296 (ESTIMATED)
- **Last updated:** 2025-05-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05998759

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05998759, "Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT05998759. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*